Controlled substances charge: Court summons Ramdev, Amazon founder

Hisar: The court of chief judicial magistrate Gitanjaali Goel in Ambala has issued summons to 14 people, including yoga guru Baba Ramdev, Acharya Balkrishna, and Amazon founder and executive chairman Jeffrey Preston Bezos, in a case alleging the use of controlled substances under the NDPS Act in Patanjali’s Divya Pharmacy product Bala Churna. All accused have been directed to appear before the court on April 13.

The summons were issued prior to the court taking cognisance of the complaint, which also alleges that the product was sold online through Amazon using a fabricated supplementary trust deed.

The complaint was filed on Nov 5, 2024, by Deepak Sandhu, an athlete from Ambala’s Dayal Bagh area. Sandhu named Divya Pharmacy, Haridwar; its trustees Baba Ramdev and Acharya Balkrishna; Patanjali Ayurved Limited; Amazon; Jeffrey Bezos; senior vice-president Amit Agarwal; and senior officials of the ministry of AYUSH and Uttarakhand AYUSH department as accused.

Those summoned include AYUSH secretary Rajesh Kotecha, joint adviser Debashish Panda, Kaustuba Upadhyay, Uttarakhand AYUSH licensing authority officer GCS Jangpangi, licensing officer Mithlesh Kumar, director Arun Kumar Tripathi, and Drug Controller General of India Rajiv Raghuvanshi.

The case invokes provisions of the Bharatiya Nyaya Sanhita, the NDPS Act, the Information Technology Act, the Drugs and Cosmetics Act, and the Drugs Rules.

Sandhu alleged that his health deteriorated after consuming ‘Bala Churna’, which he purchased through Amazon in 2019. He claimed subsequent inquiries and a test report from the Central govt’s drugs dept confirmed the presence of controlled substances — ephedrine and pseudoephedrine — constituting an offence under Section 9A of the NDPS Act.

The complaint also states that the product violated Rule 161 of the Drugs Rules, 1945, by failing to disclose ingredients, prompting a later notice from the Uttarakhand AYUSH department.

Sandhu further alleged that Divya Pharmacy issued a fraudulent supplementary trust deed in 2024 to facilitate product sales. He said he obtained prior sanction from the Ministry of AYUSH under Section 218 of BNSS to proceed against officials.

Related Posts

GLP-1 injections recalled across the US over sterility concerns

A nationwide recall of compounded tirzepatide injections in the United States has raised fresh concerns about the safety of weight-loss medicines. The recall, initiated by Apothecary Pharma LLC over concerns…

Govt allows third-party agencies to conduct departmental inspections

Bengaluru: The government has directed various departments to engage authorised third-party agencies to carry out scheduled inspections, audits and certification activities in areas where staff shortages have delayed regulatory checks.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

GLP-1 injections recalled across the US over sterility concerns

GLP-1 injections recalled across the US over sterility concerns

Govt allows third-party agencies to conduct departmental inspections

Govt allows third-party agencies to conduct departmental inspections

Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires